PSV359
Multiple Solid Tumors (FAP-α+)
Phase 1/2Enrolling (5.0 mCi)
Key Facts
Indication
Multiple Solid Tumors (FAP-α+)
Phase
Phase 1/2
Status
Enrolling (5.0 mCi)
Company
About Perspective Therapeutics
Perspective Therapeutics is a clinical-stage biotech on a mission to transform cancer treatment with its innovative targeted alpha-particle therapy (TAT) platform. Formed in 2023 via a strategic merger, the company leverages a proprietary Pb-212-based approach to deliver high-energy, short-range radiation directly to cancer cells, minimizing damage to healthy tissue. Its strategy focuses on advancing a pipeline of image-guided theranostics for neuroendocrine tumors, melanoma, and other solid tumors, positioning it at the forefront of the next wave in radiopharmaceuticals.
View full company profile